Abdul Abdirahman
Principal
F-Prime
Principal investing in early-stage B2B software, fintech, and vertical SaaS.
Bio
Professional summary
Jack Neureuter is a Senior Associate at F-Prime focused on early-stage crypto investments. Before joining F-Prime, he was an investor at Avon Ventures and a research analyst for Fidelity Digital Assets. His F-Prime portfolio page links him to crypto companies including Asymmetry Finance and Chaos Labs.
Notable companies
Selected portfolio companies the partner has backed
Asymmetry FinanceChaos LabsMeldCyclops
Background
Career, education, and skills
Career history
- F-Prime CapitalSenior AssociatePresent
- Avon VenturesInvestor
- Fidelity Digital AssetsResearch Analyst
Education
- University of Massachusetts AmherstFinance
Other partners at F-Prime
12 more profiles
Alex Pasteur
Partner
F-Prime
Alex Pasteur is a London-based Partner at F-Prime Capital focused on therapeutics and life sciences.
AP
Anastasiya Sybirna, PhD
Senior Associate
F-Prime
Senior Associate on F-Prime's London healthcare investment team.
Bala Varadhan
Principal
F-Prime
Principal focused on early-stage crypto, blockchain and Web3 investments.
Benjamin Gorman
Principal
F-Prime
Principal investing in early-stage enterprise software and AI.
Betsy Mulé
Principal
F-Prime
Principal investing in enterprise technology and robotics.
Brett Cook
Partner
F-Prime
F-Prime Partner investing in healthcare technology and services companies.
Brian Yordy
Principal
F-Prime
Principal investing in biopharmaceutical and medical technology companies.
Carl Bradford Byers 🚑
Partner
F-Prime
F-Prime Partner and former athenahealth founding CFO investing in healthcare IT and digital health.
Carl Byers
Partner
F-Prime
Carl Byers is a Partner at F-Prime Capital with significant operating experience in healthcare IT, including as a founding team member and CFO of athenahealth.
Chance Mathisen
Associate
F-Prime
Associate focused on early-stage enterprise software investments.
Chong Xu
Partner
F-Prime
F-Prime partner focused on biopharma, medtech, company formation, and China healthcare opportunities.